The North America Desalting and Buffer Exchange Market is witnessing robust growth due to rapid advancements in biopharmaceutical research and heightened demand for advanced purification solutions. The market size was valued at USD 710 Million in 2025, and it is projected to reach USD 1,620 Million by 2035 at a CAGR of 7.8% during 2024-2035. The increasing presence of global bio-pharma companies and investments in protein purification workflows are key contributors to the region’s market growth.
The economic impact of tariffs on "North America Desalting and Buffer Exchange Market".
Market Growth Drivers
Accelerating Biopharmaceutical R&D: The rising focus on monoclonal antibodies and recombinant protein therapeutics, especially in the U.S., is fueling demand for efficient desalting and buffer exchange tools. Major players like Thermo Fisher Scientific and MilliporeSigma have introduced innovative spin columns and membrane devices, optimizing the workflow in drug development labs. Biopharma companies rely on these solutions to achieve high product purity and yield, directly impacting time-to-market and compliance with regulatory standards. Such advancements are expanding the application base and encouraging further investments, propelling overall market growth.
Expansion of Contract Research and Manufacturing Organizations (CROs and CDMOs): The increasing outsourcing of drug discovery and development activities to CROs and CDMOs has enabled a broader adoption of high-throughput desalting products. Companies such as Sartorius and Cytiva are targeting this segment by offering scalable and automated buffer exchange platforms, catering to a diverse range of purification needs from small-scale studies to large-scale commercial manufacturing. This trend boosts the market as more biopharma entities leverage external expertise for quicker, cost-effective, and reliable production.
Market Trends
Adoption of Automated and High-Throughput Solutions: The market is experiencing a shift towards automation and miniaturization of purification systems. Companies like Danaher (Cytiva) and Thermo Fisher Scientific are focusing on launching systems that can process multiple samples simultaneously, reducing manual labor and minimizing human error. The increasing adoption of automated buffer exchange in bioprocessing labs is enhancing reproducibility, scalability, and reducing operational cost, which further accelerates market growth.
Integration of Single-Use Technologies: With concerns regarding cross-contamination and turnaround time, the use of disposable cartridges and single-use tangential flow filtration (TFF) devices is rising. MilliporeSigma and Pall Corporation have expanded their product portfolios to include single-use technologies for desalting and buffer exchange, catering to GMP compliance and flexible manufacturing requirements in North America. This trend aligns with the broader movement towards flexible, modular biomanufacturing.
Market Opportunities
Growth Potential in Cell and Gene Therapy Manufacturing: With increasing research activity and investment in advanced therapy medicinal products (ATMPs), new purification needs are surfacing, opening significant growth avenues for desalting and buffer exchange solution providers. Leading companies like Cytiva are developing customizable kits tailored for these novel bioprocessing workflows.
Expansion into Academic and Research Institutes: The surging funding in North American academic and medical institutes for proteomics and genomics research is creating new opportunities for suppliers of desalting technologies. Providers such as Sartorius are engaging in partnerships with universities to supply high-efficiency buffer exchange products, establishing an early market presence.
North America Desalting and Buffer Exchange Market Revenue, 2020-2035 (USD Million)
The chart illustrates a steady upward trajectory for the North American Desalting and Buffer Exchange Market from 2020 to 2035. Starting at USD 400 Million in 2020, the market reflects moderate growth through adoption in pharmaceutical and biotechnology sectors. A noticeable acceleration occurs post-2024, with revenues rising consistently due to technological innovations and a surge in clinical trials demanding efficient purification. By 2025, the market stands at USD 710 Million and is projected to more than double, reaching USD 1,620 Million by 2035, highlighting the vital role of desalting and buffer exchange in modern bioprocessing and drug development workflows.
Regional Market Share, 2025 (%)
The pie chart for 2025 highlights the U.S. as the dominant market, capturing a substantial 75% share due to its established bio-manufacturing infrastructure and strong presence of key industry players. Canada follows with 13%, leveraging increasing investments in life sciences. Mexico contributes 6%, reflecting comparatively nascent but growing biosciences activity. Rest of North America, encompassing smaller nations and territories, makes up the remaining 6%. This regional distribution underscores the pivotal role of the U.S., while neighboring regions are emerging as important secondary markets as investments in biopharmaceutical production increase.
Recent Market Developments
In May 2024, Thermo Fisher Scientific unveiled its new HyperSep SpinTip desalting devices designed for small-volume, high-throughput sample preparation in proteomics research. The innovation enables researchers to rapidly process multiple samples with improved recovery rates, catering to rising demand in clinical laboratories and drug discovery centers across North America.
In April 2024, Cytiva (Danaher) expanded its ReadyToProcess portfolio with single-use buffer exchange membranes tailored for gene therapy manufacturing workflows. This product targets CDMOs and emerging biotech firms in the region, supporting the shift towards greener, faster, and GMP-compliant bioprocessing solutions.
In March 2024, Sartorius announced a strategic partnership with a leading North American bioscience institute to co-develop an integrated desalting and buffer exchange platform for next-generation sequencing (NGS) sample prep. The collaboration aims to enhance throughput and reproducibility in academic and clinical research labs, strengthening Sartorius' foothold in the R&D segment of the market.
By Type: Ultrafiltration, Dialysis, Gel Filtration, Spin Columns, Precipitation, Others; By Application: Biopharmaceutical Production, Diagnostic Research, Vaccine Production, Protein Purification, Drug Formulation, Others
Press Releases